medigraphic.com
ISSN 0016-3813 (Print)

2016, Number 1

<< Back Next >>

Gac Med Mex 2016; 152 (1)

Clinical characteristics and treatment response in adult patients with non-Hodgkin’s chronic lymphocytic leukemia (CLL)

Sicras-Mainar A, Castro A, Navarro-Artieda R

Language: Spanish
References: 35
Page: 59-69
PDF size: 120.31 Kb.


ABSTRACT

Objective: To determine comorbidities, clinical characteristics, and treatment response in adult patients with chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). Methods: The design was observational from reviewing the medical records of patients seen in outpatient and inpatient settings. It included ≥ 50 subjects who demanded attention during the period 2008-2012 and that met specific inclusion/exclusion criteria. The main measures were: comorbidity (population group), clinical stage, patient treatment, response to treatment, overall survival, progression-free survival, and mortality. Statistical analysis: p ‹ 0.05. Results: 270 patients (CLL = 90, DLBCL = 81, FL = 99) were recruited, with a mean age of 72.5, 65.5, and 62.4 years, respectively. These groups of neoplasms, compared with the general population, showed a higher percentage of men (60.0, 56.8 and 52.6 vs. 46.2%) and morbidity (Charlson Comorbidity Index: 1.6, 1.5, 1.4 vs. 0.4, respectively; p ‹ 0.05). The administration of chemotherapy treatment was 28.9 vs. 86.4 and 90.9%, respectively (p ‹ 0.001). Overall survival at five years was 84.4, 45.0 and 68.5%, respectively (p = 0.027), while mortality rates were 17.0 vs. 35.3 and 20.6%, respectively (p = 0.041). Compared with other treatments, with administered rituximab the median progression-free survival was 6.8 vs. 4.2 years (p ‹ 0.001). These differences were maintained for the three neoplasms. Conclusions: Comorbidity associated with hematological malignancies is high. The chronic lymphocytic leukemia group showed increased survival with lower mortality rate. Rituximab showed a higher progression-free survival in these neoplasms.


REFERENCES

  1. Vandenberghe P. Genetic lesions and the malignant phenotype of haematological cancers. Verh K Acad Geneeskd Belg. 2007;69(5- 6):291-313.

  2. Dunwell T, Hesson L, Rauch TA, et al. A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol Cancer. 2010;9:44.

  3. González Rodríguez AP, González García E, Fernández Alvarez C, González Huerta AJ, González Rodríguez S. [B-chronic lymphocytic leukemia: epidemiological study and comparison of MDACC and GIMENA pronostic indexes]. Med Clin (Barc). 2009;133(5):161-6.

  4. Lu K, Wang X. Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol. 2012;5:55.

  5. Cheng MM, Goulart B, Veenstra DL, Blough DK, Devine EB. A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia. Cancer Treat Rev. 2012;38(8):1004-11.

  6. Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. Cancer Control. 2012;19(1):18-25.

  7. Bazargan A, Tam CS, Keating MJ. Predicting survival in chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2012;12(3):393-403.

  8. Audrito V, Vaisitti T, Serra S, et al. Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Lett. 2013;328(1):27-35.

  9. Mougalian SS, O’Brien S. Adverse prognostic features in chronic lymphocytic leukemia. Oncology (Williston Park). 2011;25(8):692-9.

  10. Tilly H, Vitolo U, Walewski J,et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii78-82.

  11. López-González A, Sabin P, Quero C, et al. Epidemiological analysis of follicular lymphoma in Spain: Retrospective registry in 17 hospitals. 7th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress. Ámsterdam, 27 de septiembre-1 de octubre 2013. Póster 3625.

  12. Leak A, Mayer DK, Smith S. Quality of life domains among non-Hodgkin lymphoma survivors: an integrative literature review. Leuk Lymphoma. 2011;52(6):972-85.

  13. Zhuang Y, Xu W, Shen Y, Li J. Fcγ receptor polymorphisms and clinical efficacy of rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2010;10(5):347-52.

  14. Hagemeister F. Rituximab for the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs. 2010;70(3):261-72.

  15. Casado LF, García Marco JA, Gilsanz F, et al. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia]. Gac Sanit. 2011;25(4):274-81.

  16. García Marco JA, Giraldo Castellano P, López Jiménez J, et al. [National guidelines for the management of patients with chronic lymphocytic leukemia. Sociedad Española de Hematología y Hemoterapia and Grupo Español de Leucemia Linfocítica Crónica]. Med Clin (Barc). 2013;141(4):175.e1-8.

  17. Lamberts H, Wood M, Hofmans-Okkes IM, eds. The International Classification of Primary Care in the European Community. With a multi-language layer. Oxford: Oxford University Press; 1993.

  18. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-56.

  19. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-61.

  20. Arcaini L, Merli M, Passamonti F, et al. Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol. 2010;149(3):455-7.

  21. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.

  22. Weiner JP, Starfield BH, Steinwachs DM, Mumford LM. Development and application of a population-oriented measure of ambulatory care casemix. Med Care. 1991;29(5):452-72.

  23. Panovska A, Doubek M, Brychtova Y, Mayer J. Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). Clin Lymphoma Myeloma Leuk. 2010; 10(4):297-300.

  24. Marcos-Gragera R, Vilardell L, Izquierdo A, et al. [Population-based incidence of lymphoid neoplasms by histological subtypes in Girona (Spain), 1994-2001]. Med Clin (Barc). 2006;126(1):5-12.

  25. Bosetti C, Levi F, Ferlay J, Lucchini F, Negri E, La Vecchia C. Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic? Int J Cancer. 2008;123(8):1917-23.

  26. Geneviève F, Delisle V, Gardembas M, Foussard C, Gardais J, Zandecki M. Chronic lymphoid hemopathies in adults: chronic lymphocytic leukaemia and the phase of dissemination of small cell lymphomas. Ann Biol Clin (Paris). 2001;59(4):403-15.

  27. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi50-4.

  28. Charafeddine KM, Jabbour MN, Kadi RH, Daher RT. Extended use of serum free light chain as a biomarker in lymphoproliferative disorders: a comprehensive review. Am J Clin Pathol. 2012;137(6):890-7.

  29. Bazargan A, Tam CS, Keating MJ. Predicting survival in chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2012;12(3):393-403.

  30. Delgado J, Espinet B, Oliveira AC, et al. Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. Br J Haematol. 2012;157(1):67-74.

  31. Perry AM, Mitrovic Z, Chan WC. Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control. 2012;19(3):214-26.

  32. Feng J, Wang Z, Guo X, Chen Y, Cheng Y, Tang Y. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis. Int J Hematol. 2012;95(2):143-8.

  33. Solal-Céligny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol. 2010;92(2):246-54.

  34. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. J Clin Oncol. 2010;28(17): 2902-13.

  35. Robak T. Rituximab for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2012;12(4):503-15.




2020     |     www.medigraphic.com